Entrada Therapeutics (TRDA) Competitors $17.59 +0.31 (+1.79%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends TRDA vs. DYN, HCM, CPRX, AGIO, PTGX, IOVA, AMRX, LBPH, NAMS, and IDYAShould you be buying Entrada Therapeutics stock or one of its competitors? The main competitors of Entrada Therapeutics include Dyne Therapeutics (DYN), HUTCHMED (HCM), Catalyst Pharmaceuticals (CPRX), Agios Pharmaceuticals (AGIO), Protagonist Therapeutics (PTGX), Iovance Biotherapeutics (IOVA), Amneal Pharmaceuticals (AMRX), Longboard Pharmaceuticals (LBPH), NewAmsterdam Pharma (NAMS), and IDEAYA Biosciences (IDYA). These companies are all part of the "pharmaceutical products" industry. Entrada Therapeutics vs. Dyne Therapeutics HUTCHMED Catalyst Pharmaceuticals Agios Pharmaceuticals Protagonist Therapeutics Iovance Biotherapeutics Amneal Pharmaceuticals Longboard Pharmaceuticals NewAmsterdam Pharma IDEAYA Biosciences Entrada Therapeutics (NASDAQ:TRDA) and Dyne Therapeutics (NASDAQ:DYN) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, analyst recommendations, community ranking, earnings, dividends and profitability. Is TRDA or DYN more profitable? Entrada Therapeutics has a net margin of 25.53% compared to Dyne Therapeutics' net margin of 0.00%. Entrada Therapeutics' return on equity of 16.11% beat Dyne Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Entrada Therapeutics25.53% 16.11% 10.39% Dyne Therapeutics N/A -57.46%-51.62% Does the MarketBeat Community believe in TRDA or DYN? Dyne Therapeutics received 15 more outperform votes than Entrada Therapeutics when rated by MarketBeat users. However, 81.82% of users gave Entrada Therapeutics an outperform vote while only 73.33% of users gave Dyne Therapeutics an outperform vote. CompanyUnderperformOutperformEntrada TherapeuticsOutperform Votes1881.82% Underperform Votes418.18%Dyne TherapeuticsOutperform Votes3373.33% Underperform Votes1226.67% Which has preferable valuation and earnings, TRDA or DYN? Entrada Therapeutics has higher revenue and earnings than Dyne Therapeutics. Dyne Therapeutics is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEntrada Therapeutics$215.23M3.06-$6.68M$1.5911.06Dyne TherapeuticsN/AN/A-$235.94M-$3.56-6.74 Do analysts recommend TRDA or DYN? Entrada Therapeutics currently has a consensus price target of $25.67, suggesting a potential upside of 45.92%. Dyne Therapeutics has a consensus price target of $50.42, suggesting a potential upside of 110.16%. Given Dyne Therapeutics' higher probable upside, analysts plainly believe Dyne Therapeutics is more favorable than Entrada Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Entrada Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Dyne Therapeutics 0 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 3.08 Does the media favor TRDA or DYN? In the previous week, Dyne Therapeutics had 5 more articles in the media than Entrada Therapeutics. MarketBeat recorded 6 mentions for Dyne Therapeutics and 1 mentions for Entrada Therapeutics. Entrada Therapeutics' average media sentiment score of 1.11 beat Dyne Therapeutics' score of 0.98 indicating that Entrada Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Entrada Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dyne Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, TRDA or DYN? Entrada Therapeutics has a beta of -0.18, meaning that its stock price is 118% less volatile than the S&P 500. Comparatively, Dyne Therapeutics has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500. Do insiders & institutionals have more ownership in TRDA or DYN? 86.4% of Entrada Therapeutics shares are held by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are held by institutional investors. 7.6% of Entrada Therapeutics shares are held by insiders. Comparatively, 20.8% of Dyne Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. SummaryEntrada Therapeutics beats Dyne Therapeutics on 10 of the 18 factors compared between the two stocks. Ad Brownstone ResearchMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.Click here to watch this demo and decide for yourself. Get Entrada Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TRDA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TRDA vs. The Competition Export to ExcelMetricEntrada TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$658.22M$6.57B$5.10B$9.08BDividend YieldN/A2.97%4.90%4.21%P/E Ratio11.0610.5090.8717.14Price / Sales3.06195.381,112.67116.85Price / CashN/A57.1642.1437.88Price / Book2.425.104.784.78Net Income-$6.68M$151.51M$119.77M$225.60M7 Day Performance-0.40%-2.12%-1.87%-1.23%1 Month Performance-2.55%-3.11%11.46%3.07%1 Year Performance19.17%11.52%30.49%16.48% Entrada Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TRDAEntrada Therapeutics2.8936 of 5 stars$17.59+1.8%$25.67+45.9%+17.3%$658.22M$215.23M11.06110Positive NewsGap DownHigh Trading VolumeDYNDyne Therapeutics3.1221 of 5 stars$26.05+1.2%$50.42+93.5%+104.9%$2.65BN/A-7.23100HCMHUTCHMED2.5927 of 5 stars$14.94-4.1%$19.00+27.2%-15.0%$2.60B$838M0.001,988Gap DownCPRXCatalyst Pharmaceuticals4.6873 of 5 stars$21.78+1.9%$31.14+43.0%+48.7%$2.60B$398.20M18.12167AGIOAgios Pharmaceuticals4.2862 of 5 stars$44.19+13.4%$56.33+27.5%+53.6%$2.52B$32.87M3.73390Analyst ForecastPTGXProtagonist Therapeutics3.582 of 5 stars$41.53+1.1%$53.78+29.5%+100.0%$2.48B$60M15.44125News CoveragePositive NewsIOVAIovance Biotherapeutics3.9934 of 5 stars$7.93+1.3%$22.33+181.6%+2.8%$2.42B$1.19M-5.25500AMRXAmneal Pharmaceuticals2.8899 of 5 stars$7.75-1.0%$10.00+29.0%+47.1%$2.40B$2.68B-11.387,700Analyst DowngradeNews CoveragePositive NewsLBPHLongboard Pharmaceuticals0.6607 of 5 stars$59.98+0.0%$59.56-0.7%+986.6%$2.34BN/A-26.9020NAMSNewAmsterdam Pharma2.8436 of 5 stars$24.50-0.8%$36.20+47.8%+142.4%$2.26B$33.59M0.0057Insider TradeAnalyst RevisionGap DownIDYAIDEAYA Biosciences4.3209 of 5 stars$25.95+3.0%$53.67+106.8%-23.7%$2.24B$3.92M-10.8180Analyst Forecast Related Companies and Tools Related Companies Dyne Therapeutics Alternatives HUTCHMED Alternatives Catalyst Pharmaceuticals Alternatives Agios Pharmaceuticals Alternatives Protagonist Therapeutics Alternatives Iovance Biotherapeutics Alternatives Amneal Pharmaceuticals Alternatives Longboard Pharmaceuticals Alternatives NewAmsterdam Pharma Alternatives IDEAYA Biosciences Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TRDA) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entrada Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Entrada Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TRDA Stock Alerts